were typically obtained from the mid thigh, and the distal segments from the calf. Subjects were matched for age, sex, and the major risk factors for atherosclerosis, known from previous stud ies to affect vascular oxidative stress and super oxide production. Lowmolecularweight hep arins, if used, were discontinued 24 hours pri or to the surgery. Vessel segments were har vested using a notouch technique, before sur gical distension (HSV) or rapid removal of VV. The segments were immediately transferred to ice cold KrebsHEPES buffer (99 mmol/l NaCl; 4.7 mmol/l KCl; 1.2 mmol/l MgSO 4 ; 1 mmol/l KH 2 PO 4; 1.9 mmol/l CaCl 2 ; 25 mmol/l NaHCO 3 ; 11.1 mmol/l glucose; and 20 mmol/l HEPES), del icately flushed, and carefully dissected to remove excess adventitial tissue, using microsurgical in struments. All vessels were collected before top ical administration of drugs such as papaverine. The collection of tissue specimens was approved by the Local Research Ethics Committee and in formed consent was obtained.
vascular superoxide production Superoxide pro duction was measured by lucigeninenhanced chemiluminescence (LGCL), using the previous ly described and validated methods. 13, 19 Brief ly, intact vessel segments were equilibrated in KrebsHEPES gassed with 95%O 2 /5%CO 2 for 30 minutes at 37ºC. LGCL from intact vessels was measured in buffer (2 ml) containing lowconcen tration lucigenin (5 µmol/l). Superoxide produc tion was expressed as relative light units (RLU) per second per mg of dry weight of the vessel (RLU/s/mg dw).
determination of the sources of vascular superoxide production Superoxide release was measured in the presence of various potential oxidase inhibi tors to determine its sources in VV. These inhibi tors included diphenyliodonium (DPI, 10 µmol/l, flavin oxidase inhibitor such as nicotinamide ad enine dinucleotide phosphate [NADPH] oxidase), apocynin (Apoc; 300 µmol/l; NADPH oxidase in hibitor); oxypurinol (Oxy; 100 µmol/l; xanthine oxidase inhibitor); nitroLarginine methyl ester (LNAME; 100 µmol/l; nitric oxide synthase inhibi tor); and rotenone (Rot; 100 µmol/l; mitochondrial oxidase inhibitor). As described above, superoxide production was expressed as RLU/s/mg dw. statistical analysis The results are expressed as means ± standard error of the mean with "n" equal to the number of patients. Statistical com parisons between the 2 groups were made using the t test for independent or dependent vari ables. P values <0.05 were considered statisti cally significant.
rEsuLts clinical characteristics of the patients
Vessels were obtained from 29 patients (14 sub jects undergoing VV surgical removal and 15 con trol nonvaricose subjects undergoing elective CABG). Demographic and clinical characteristics, unknown. 6 Endothelial dysfunction is one of the possible mechanisms. 7 Recently, it has been suggested that oxidative stress is increased in VV. [8] [9] [10] Increased reactive oxygen species (ROS) production has been implicated in the genesis of endothelial dysfunction characterized by the loss of protective nitric oxide (NO) bio availability 11 in numerous vascular disease states associat ed with atherosclerosis, diabetes, hypertension, and smoking. 12-14 Finally, several recent studies have linked endothelial dysfunction with the de velopment of subsequent venous valve dysfunc tion, which underlies VV formation. 7 Moreover, oxidative stress, through its effects on matrix meta lloproteinases (MMP), could be an impor tant contributor to venous remodeling. 15 ROS cause oxidation of lipid membranes and proteins; they are also critical regulators of inflammation. Moreover, we have previously shown that vascu lar oxidative stress is a systemic phenomenon re lated primarily to clinical risk factors. 16, 17 While initial studies have focused on the role of super oxide production and oxidative stress in the ar teries, we have shown that it is also very prom inent in human veins and may play a role in hu man pathology. 16, 18 Despite this evidence, the role of ROS in hu man varicose vein disease has not been well de fined. Two recent studies have shown that oxida tive stress is increased in VV, particularly in insuf ficient vessels.
8,9 However, they focused primari ly on antioxidant enzymes and used indirect and unspecific methods of ROS assessment, such as determination of malondialdehyde (MDA) con centration. While MDA is a product of oxidation by ROS, its generation in bio logical systems is complex and does not allow for specific identifi cation of individual ROS species involved. 8 There fore, it is critical to understand which ROS are pri marily involved in oxidative stress, and to further define its enzymatic mechanisms in VV. Thus, in the present study we aimed to measure super oxide anion production from varicose vein seg ments in comparison with nonvaricose human sa phenous vein (HSV) samples, obtained from sub jects undergoing elective coronary artery bypass grafting (CABG). We also analyzed the enzymat ic sources of superoxide production in VV. Finally, we compared superoxide production in the proxi mal and distal segments of the veins (control and varicose) in order to gain insight into the role of different degrees of blood reflux and stagnation. This could also shed light on the role of venous pressure increase in the regulation of vascular ox idative stress in VV.
PAtIEnts And mEthods Patients and blood vessels
The proximal and distal segments of HSV were obtained from subjects with varicose vein dis ease (VV; n = 14) undergoing VV removal sur gery and from subjects without the disease un dergoing elective CABG (excess vein obtained from the proximal and distal vein segments were compared; HSV; n = 15). The proximal segments shown in the tAbLE, demonstrate that patients were matched for age, sex, and the major risk factors for atherosclerosis known to affect vas cular oxidative stress. Patient characteristics and the risk factor profile were typical for patients with atherosclerosis.
superoxide production from varicose and nonvaricose veins Superoxide production, determined by LGCL from intact vascular rings, was observed in all studied vessels and was significantly higher in VV than in the control vessels (FIGurE 1). This increase was observed in both proximal and dis tal segments of the vessels. A detailed analysis showed that there was almost a 2fold increase in basal superoxide production in the distal seg ments of VV (but not of the nonvaricose control vessels), when compared with the proximal seg ments (FIGurE 1).
Specificity for superoxide detection was con firmed by coincubation with superoxide dis mutase (SOD). Preincubation with polyethyl ene glycolconjugated SOD (500 U/ml), result ed in a very significant inhibition of LGCL signal (92 ±6% inhibition in control HSV and 93 ±8% inhibition in VV; n = 5; data not shown).
relationships between proximal and distal superoxide production To gain further insight into the differ ences in superoxide production between the prox imal and distal segments of the studied veins, we analyzed the relationship between the abso lute amounts of superoxide produced by proximal and distal segments either in the control veins or in VV. Interestingly, superoxide production was very significantly correlated between the proxi mal and distal vascular segments in nonvaricose veins, but not in VV (FIGurE 2). sources of vascular superoxide production in human varicose disease To investigate enzymatic sourc es of superoxide production in VV, we measured superoxide production from distal vascular seg ments following preincubation with a range of potential oxidase inhibitors (FIGurE 3). Superoxide the relationships between superoxide production in the proximal and distal vessel segments. In terestingly, while in nonvaricose HSVs there was a strong correlation of superoxide production be tween the proximal and distal segments, such re lationship was not observed in VV. This may in dicate that while the systemic factors are most critical in the regulation of superoxide produc tion in nonvaricose veins, in VV the local factors may play an important role that exceeds the ef fect of systemic regulation of oxidative stress in humans. We have previously identified a system ic nature of both endothelial dysfunction and ox idative stress in patients with atherosclerosis. 16 Endothelial function, superoxide production, and major vascular oxidase expression are all correlat ed not only between different areas of one vascu lar bed, but also in functionally distinct vascular compartments, such as the venous and arterial systems. 16 A multivariate analysis performed in these studies showed that the major risk factors for atherosclerosis are the main regulators of sys temic vascular oxidative stress. 17 In particular, di abetes and hypercholesterolemia have been de fined as the main factors increasing superoxide production in the veins. However, the results of the present study show that apart from systemic effects, local disease environment may be impor tant in enhancing superoxide production and ox idative stress in VV. Lack of correlation between superoxide production in the proximal and distal segments of VV may indicate that such factors as different degrees of blood reflux and stagnation or variable venous pressure have stronger effects than systemic factors. Alternatively to pressure changes, it is possible that certain locally released humoral factors, such as chemokines or cytokines, or certain hypoxiarelated meta bolites may exert stimulatory effects on ROS production in the dis tal parts of VV. 20 This may be related to the prop agation of VV rather than only to their initiation. Obviously, this hypothesis requires further direct longitudinal studies in larger cohorts, to deter mine whether local pressure related factors or au tacoids play the major role in this disease.
Our study is in line with the previous studies that measured oxidative stress markers in VV and showed a significant increase of MDA, which was also related to venous insufficiency. Krzyściak and Kózka 8 demonstrated increased oxidative stress in insufficient veins and showed that the degree of oxidative damage may correlate with clinical degree of venous disease.
However, our study adds to that knowledge by assessing superoxide production directly from vascular segments, rather than indirectly by de termination of lipid oxidation products. Inter estingly, previous studies also demonstrated that SOD activity is increased in VV or venous insuf ficiency. The role of the balance between proox idant and antioxidant enzymes in numerous patho logies has been identified, including can cer, 21 acute coronary syndromes, 22 renal dysfunc tion, 23 and asthma.
24 While we have not described production was very significantly inhibited by di phenylene iodonium, an inhibitor of flavin con taining oxidases such as NADPH oxidases. Simi lar degree of inhibition was observed in the pres ence of apocynin, which is considered a relatively specific inhibitor of NADPH oxidase. Oxypurinol and rotenone had minimal effects on superox ide production from VV. However, the response to inhibition of NOS with LNAME demonstrat ed very consistent (about 25%), statistically sig nificant inhibition of superoxide production in all the vessels, indicating important contribu tion of NOS to oxidative stress rather than NO production in VV.
dIscussIon We have compared superoxide pro duction between varicose and nonvaricose veins and used the proximal and distal segments of these vessels as a model system to assess the ef fects of venous pressure increase in the regula tion of vascular oxidative stress in human veins. Our study has demonstrated for the first time that VV generate significantly more superoxide anions. Importantly, increased venous blood pres sure related to blood reflux and stagnation ob served in the distal segments of VV is associated with a further increase in superoxide anion pro duction. At the same time, in nonvaricose veins, with the fully functional venous valve system, su peroxide production is not increased in the dis tal segments of HSV. To gain further insight into the nature (local or systemic) of the factors that regulate superoxide production in VV, we studied FIGurE 3 Enzymatic sources of superoxide anion in human varices. Superoxide production was determined by LGCL (5 µmol/l) in the absence and presence of various oxidase inhibitors. Distal varicose vein segments were incubated for 30 minutes before and during superoxide determination with: diphenyleneiodonium (DPI; 10 µmol/l); apocynin (Apoc; 300 µmol/l); oxypurinol (Oxy; 100 µmol/l); nitro-L-arginine methyl ester (L-NAME; 100 µmol/l); and rotenone (Rot; 100 µmol/l). a P <0.05 vs. native Abbreviations: NADPH -nicotinamide adenine dinucleotide phosphate, NOS -nitric oxide synthase, others -see FIGurE 1
LGCL (RLU/s/mg dw) results in the formation of another strong oxi dant, peroxynitrite. We previously described this reaction and its consequences in normal human veins. 11 ROS may also directly damage cell lipid mem branes. 30 This leads to concomitant cellular inju ry of either endothelium or smooth muscle cells, as well as lipid raft dysfunction that may result in vascular and venous valve dysfunction.
30 ROS are also involved in the induction of inflamma tory reactions, thus contributing to the role of immune reactions 31 that may occur and enhance vascular damage in varicose vein disease. Finally, ROS are potent inducers of MMP. They both in crease the activity and expression of MMP9 and are able to inhibit tissue inhibitors of MMP.
9,32
All of these factors may be critical for the initia tion of venous dysfunction and may lead to de creased velocity of blood flow through the vein, which further exacerbates the patho logical chang es. This may lead to venous dysfunction with de creased blood flow. Blood retracts and accumu lates in the peripheral segments of the veins lead ing to venous pressure increase and vascular wall dilation.
6 Vein tension and hypoxia activate vas cular wall cells and infiltration of leukocytes into vascular wall 33 closing the vicious circle of VV for mation. Many of the risk factors known to affect the development of chronic venous insufficiency, that in the present study, we were unable to de fine clear differences in either SOD activity or expression in human VV (data not shown). This is in line with our previous studies showing that CuZn SOD or MnSOD expression and activity were unchanged in human veins in coronary ar tery disease. 25 We did not, however, assess ex tracellular SOD levels, which could actually be the most important dismutase variant in vari cose vein disease.
ROS, and in particular superoxide anions, may play numerous roles in the pathogenesis of chronic venous insufficiency and varicose vein disease.
10,26
In general, the current view of the initiation of varicose vein disease include increased destruc tion of collagen and matrix proteins which are initiated by endothelial dysfunction, character ized by loss of NO and prostacyclin (PGI 2 ) bio availability and subsequently increased vascular inflammation, initiated by increased adherence of leukocytes to venous endothelium.
5,6,15,27 ROS may regulate these processes on a number of lev els (FIGurE 4) . First, superoxide anion is the most important cause for bio degradation of NO in hu man blood vessels. 28 The reaction of NO with su peroxide was experimentally demonstrated for the first time by Gryglewski et al. 29 This rapid re action, exceeding Km of any antioxidant enzymes, such as ischemia 34 or angiotensin II, 8 lead to in creased superoxide and other ROS production through the activation of oxidases. The present study showed that O 2 -. production was increased in the distal segments of VV, which are character ized by increased hemo dynamic pressure. These findings point to the role of ROS in the propa gation of varicose disease because their produc tion seems to be further enhanced by local hemo dynamic factors.
We have been the first to show the direct mea sure of superoxide production from VV, but our study has some limitations. First, it would be in formative to compare further clinical character istics of venous functions with measures of su peroxide production. Such comparisons, howev er, would be particularly valuable in larger study populations, where a multivariate analysis would have to be applied to unequivocally identify clini cal determinants of superoxide production in VV, which is very important from the clinical point of view. We used LCGL to measure superoxide pro duction. 35 This approach has been criticized in the past, particularly, in relation to the use of high concentrations of lucigenin (above 20 µmol/l) which could artificially enhance superoxide detec tion through redox cycling. 35 Thus, in the present study, we used low concentrations of lucigenin, which are highly validated measures of superox ide production and are free from the problem of redox cycling.
In summary, the present study has demon strated for the first time that VV produce in creased amounts of superoxide anion compared with normal nonvaricose veins, particularly in the distal segments of the varices. NADPH oxi dases are the primary sources of superoxide an ion in VV, in line with the earlier findings in nor mal, control veins from atherosclerotic subjects. Our study, considered together with the previ ous descriptions of increased oxidative stress in human varicose vein disease, indicates that an tioxidant approaches could be valuable in treat ing venous dysfunction. These could include un specific approaches, such as Nacetylcysteine or sulodexide treatments, 23 or a typical antioxidant vitamin approach. 36, 37 However, these methods should rather be local and possibly directed to wards the inhibition of NADPH oxidase activity in these veins. Further clinical studies are need ed to confirm this inter esting possibility.
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